Please assess the completion status of the following clinical trial:

Trial Title: Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, subject informed assent) to participate in the study before completing any study-related procedures.~2. Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).~3. Subject understands and is willing and able to fully adhere to study requirements as defined in this protocol.~Exclusion Criteria:~There are no exclusion criteria for this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SOC) Treatment +/- Teduglutide (Type: EXPERIMENTAL): TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).